Leonie Müller-Jensen, Axel R Schulz, Henrik E Mei, Raphael Mohr, Claas Ulrich, Philipp Knape, Nikolaj Frost, Stefan Frischbutter, Desiree Kunkel, Christian Schinke, Lorena Ginesta Roque, Smilla K Maierhof, Florian T Nickel, Lucie Heinzerling, Matthias Endres, Wolfgang Boehmerle, Petra Huehnchen, Samuel Knauss
BACKGROUND: Neurologic immune-related adverse events (irAE-n) are rare but severe toxicities of immune checkpoint inhibitor (ICI) treatment. To overcome diagnostic and therapeutic challenges, a better mechanistic understanding of irAE-n is paramount. METHODS: In this observational cohort study, we collected serum and peripheral blood samples from 34 consecutive cancer patients with irAE-n (during acute illness) and 49 cancer control patients without irAE-n (pre- and on-ICI treatment, n = 44 without high-grade irAEs, n = 5 with high-grade nonneurologic irAEs)...
October 12, 2023: Neuro-oncology